Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping.

The pharmaceutical company’s earning and revenue were better than expected. (Michael Nagle/Bloomberg)

Shares of Regeneron Pharmaceuticals were rising Friday after the biopharmaceutical company’s revenue and earnings comfortably surpassed Wall Street’s expectations.

The Tarrytown, N.Y.-based company posted adjusted earnings of $12.89 a share for the second quarter, surpassing analysts’ consensus estimate of $8.43, according to FactSet. Revenue totaled $3.68 billion, a 4% jump from last year and above Wall Street’s call for $3.29 billion.

Regeneron stock was up 6.4% in premarket trading Friday, making it the top performer in the S&P 500 before Wall Street opens, per FactSet.

U.S. sales of Eylea HD and Eylea, treatments for eye conditions like wet age-related macular degeneration, decreased 25% in the quarter from last year but exceeded analysts’ expectations. The company cited competitive pressures, a decline in market share, a lower selling price, and the transition of patients to Eylea HD from Eylea as reasons for the drop.

Regeneron made up for it with strong global sales of Dupixent, its medication for various forms of inflammation. Sales of Dupixent, which are recorded by Sanofi and logged as collaboration revenue by Regeneron, rose 22% from 2024.

Sanofi collaboration revenue totaled $1.44 billion for the quarter, ahead of Wall Street’s call for $1.3 billion.

Write to Nate Wolf at nate.wolf@barrons.com